Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Engineering DNA vaccines against infectious diseases

Jihui Lee, Shreedevi Arun Kumar, Yong Yu Jhan, Corey J. Bishop

Department of Biomedical Engineering, Texas A&M University, Emerging Technologies Building, 101 Bizzell St., College Station, TX 77843, USA

ABSTRACT

Engineering vaccine-based therapeutics for infectious diseases is highly challenging, as trial formulations are often found to be nonspecific, ineffective, thermally or hydrolytically unstable, and/or toxic. Vaccines have greatly improved the therapeutic landscape for treating infectious diseases and have significantly reduced the threat by therapeutic and preventative approaches. Furthermore, the advent of recombinant technologies has greatly facilitated growth within the vaccine realm by mitigating risks such as virulence reversion despite making the production processes more cumbersome. In addition, seroconversion can also be enhanced by recombinant technology through kinetic and nonkinetic approaches, which are discussed herein. Recombinant technologies have greatly improved both amino acid-based vaccines and DNA-based vaccines. A plateau of interest has been reached between 2001 and 2010 for the scientific community with regard to DNA vaccine endeavors. The decrease in interest may likely be attributed to difficulties in improving immunogenic properties associated with DNA vaccines, although there has been research demonstrating improvement and optimization to this end. Despite improvement, to the extent of our knowledge, there are currently no regulatory body-approved DNA vaccines for human use (four vaccines approved for animal use). This article discusses engineering DNA vaccines against infectious diseases while discussing advantages and disadvantages of each, with an emphasis on applications of these DNA vaccines.

Statement of Significance

This review paper summarizes the state of the engineered/recombinant DNA vaccine field, with a scope entailing “Engineering DNA vaccines against infectious diseases”. We endeavor to emphasize recent advances, recapitulating the current state of the field. In addition to discussing DNA therapeutics that have already been clinically translated, this review also examines current research developments, and the challenges thwarting further progression. Our review covers: recombinant DNA-based subunit vaccines; internalization and processing; enhancing immune protection via adjuvants; manufacturing and engineering DNA; the safety, stability and delivery of DNA vaccines or plasmids; controlling gene expression using plasmid engineering and gene circuits; overcoming immunogenic issues; and commercial successes. We hope that this review will inspire further research in DNA vaccine development.

© 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
1. Introduction

Infectious diseases are caused by a variety of microorganisms including bacteria and viruses and can often lead to a decrease in the quality of life and increased (risks of) mortality. In 2016, 1.6 million people died due to human immunodeficiency virus (HIV) alone. The infectious disease burden can be delineated using disability-adjusted life years (DALYs). Infectious diseases were listed by the World Health Organization (WHO) as a number of the top contributing issues. With regard to what was infectious disease-related, the DALYs for lower respiratory infectious diseases, HIV/AIDS, and tuberculosis were 1939, 855, and 763 per 100,000, and were ranked as 2nd, 11th, and 12th, respectively, in 2015 [1]. Various therapeutic and preventative interventions have been used to combat infectious diseases. Vaccination in particular has played a critical role in preventing, treating, and even eradicating diseases (i.e., smallpox). Poliomyelitis or polio is another deadly infectious disease that mainly affects children. The inactivated polio vaccine and oral polio vaccine are two types of vaccines that helped reduce polio by 99% worldwide; and now 80% of the population worldwide live in polio-free regions [2,3]. As of 2016, inactivated polio vaccine immunizations have helped to globally eradicate wild poliovirus type 2 serotype.

Polio vaccines remain effective despite the evolution of the virus because an antigen was selected which generates antibodies against a conserved region. However, for other pathogens with hypervariability, vaccine efficacy may be more limited. DNA vaccines can be used to overcome this challenge, as the engineered DNA can encode specific antigens. DNA recombinant-based subunit vaccines have been known to have enhanced stability, to a degree, for transportation and storage in comparison to traditional protein-based vaccines. There is greater control over the risks of virulence reversion when using DNA vaccines; therefore, DNA vaccines are considered in some aspects to be safer. Because of this, DNA vaccines can have potentially greater utility for immunocompromised patients. However, there are remaining issues that must be resolved for enabling DNA vaccines to be clinically translated for human use. The main remaining issue is the lack of immunogenicity associated with DNA vaccines. The current state of DNA vaccines is discussed within this review article.

More specifically, this review discusses: recombinant DNA subunit vaccines; mechanisms of internalization and processing; enhancing the duration of protection through nonkinetic approaches; manufacturing and engineering DNA; the safety and stability of DNA vaccines; plasmid delivery; controlling gene expression by plasmid engineering and gene circuits; overcoming immunogenic issues of DNA vaccines; examples of successful commercial DNA vaccine; and also reports our perspectives on future directions in the field.

2. Recombinant DNA subunit vaccines

A brief overview of vaccine classifications is found in Table 1. Extensive reviews have been written containing information regarding vaccine classifications, namely: live attenuated vaccines [4]; polysaccharide vaccines [5,6]; inactivated vaccines [7]; and DNA vaccines [4–8]. Fig. 1 shows the number of publications between 1931 and April 2018 for different types of vaccines, which can be an indicator of popularity. We report values based on PubMed results using EndNote between 1931 and 2020, where the projected values, as indicated by an asterisk ‘*’ for 2011–2020, were calculated by multiplying the current values by the ratio 120/87.5 (number of total months within the timeframe of interest divided by the number of months to date). DNA vaccines, in particular, show an increased number of PubMed results when compared to other vaccine types. However, the hype of DNA vaccines is dampened, thereby reaching a plateau, likely owing to difficulties in achieving sufficient immunogenic levels for protection. DNA vaccines, however, can be engineered to have effectively zero risk for virulence reversion.

For recombinant DNA subunit vaccines, a replicating vector, typically yeast or bacteria, is transformed with an engineered DNA sequence for transcription and translation and can then be administered to the patient. For instance, the hepatitis B DNA vaccine is based on different domains of the hepatitis B virus' surface antigen (HBsAg) and is often administered with an adjuvant to improve immunogenicity [9,10]. DNA vaccines encode for antigens that then mainly elicit humoral immune response similar to that of natural infection [11]. Hepatitis B DNA vaccines are often administered using liposomal or cationic carriers.
Table 1
Generalized qualitative comparisons of vaccine classifications. Please note that a few exceptions may contradict the generalized qualitative comparisons. Details on administration routes, advantages and disadvantages regarding production, immunogenicity, biosafety, transportation/storage, and examples of commercialized DNA- and amino acid-based vaccines for each vaccine classification are tabulated. The '+' and '-' denote general pros and cons.

| Further Classification | Live attenuated vaccines | Killed or Inactivated vaccines | Inactivated toxoid vaccines | Polysaccharide vaccines | Conjugate polysaccharide vaccines | Recombinant protein vaccines | DNA vaccines |
|------------------------|-------------------------|--------------------------------|---------------------------|------------------------|--------------------------------|-----------------------------|-------------|
| Administration         | Whole-cell vaccines     | Whole-cell vaccines            | i.e., Intramuscular       | Subunit vaccines        | Subunit vaccines                | Subunit vaccines            | i.e., Intramuscular         |
|                        | i.e., Subcutaneous, percutaneous, oral, intranasal | i.e., Intramuscular           | i.e., Intramuscular, subcutaneous | Subunit vaccines        | Subunit vaccines                | Subunit vaccines            | i.e., Intramuscular, Mucosal |
| Production             | – Bacteria applications | – Low-cost production         | – Toxin purification      | + Bacterial capsule components | – Protein folding               | – Protein degradation      | + Molecular stability        |
|                        | + Virus culture         | + Large-scale production      | procedures                |                        | + Encapsulation                 |                            | + Encapsulation             |
|                        | + Large-scale production| – Biocontainment              |                          |                        |                              |                            | + Animal applications       |
|                        | – Biocontainment        |                                |                          |                        |                              |                            | – Human applications        |
| Immunogenicity         | + Natural infection     | + Natural infection           | + Multiple doses          | + Molecular pathogen    | + Stimulus by Conjugation      | – Multi doses               | + Particle design           |
|                        | + Immunization efficiency| – Multiple doses              | + Adjuvant use            | – Multi doses          | – Conjugation                 | – Adjuvant use              | – Multiple doses            |
|                        | + Single or few doses   |                                | – Adjuvant use            | – Adjuvant use         | – Multiple doses              | – Adjuvant use              | – Adjuvant use              |
|                        | + Life-long protection  |                                |                            |                        |                                |                            |                            |
| Biosafety              | – Risk of infection     | + Safer than LAVs              | + Fewer side effects     | + No live pathogenic components | + Fewer side effects          |                            | + No live components        |
|                        | – Risk of reversion     |                                |                            |                        |                                |                            | + Fewer side effects        |
|                        | – Risk for the immuno-incompetent | |                            |                        |                                |                            | – Autoimmune response       |
| Storage and Transportation | – Cold chain delivery | – Cold chain delivery          | + Less need for cold chain delivery | Decavac, Tenivac       | + Less need for cold chain delivery | PedvaxHIB, Hibrix, Comvax, Prevnar 13 | + Less need for cold chain delivery |
| Licensed vaccines (trade names) | M-M-R II, OPV, FluMist, Rotarix, ProQuad, Adenovirus, Zostavax | Pediarix, Ipol, BioThrax, Infanrix, Daptacel, Gardasil, Cervarix, Flublok | + Less need for cold chain delivery | Menomune, Pneumovax 23 | + Less need for cold chain delivery |                            | + Less need for cold chain delivery |
DNA and protein vaccines share a major part of the production process but vary in the mechanisms elicited by the immune system. The first step consists of inserting the gene of interest (GOI) into the plasmid vector, followed by transformation into replicating bacteria or yeast. After the replication, the recombinant protein is extracted, purified, and prepared as a vaccine. In the case of DNA vaccines, the replicating vector is usually disrupted and the engineered DNA is extracted and purified to produce the final vaccine. After administration to the patient, recombinant protein vaccines are internalized within the host cells and processed to antigenic peptides, which elicit CD8+ T cell responses. The DNA vaccine must achieve being internalized by the nucleus to use the host molecular machinery to promote the transient expression of the GOI. After the transcription and translation of the GOI, it is processed to antigenic peptides, and these antigenic peptides elicit immune responses.

In the case of a DNA vaccine, the engineered DNA can be administered to the patient with or without (i.e., gene gun) a carrier. Generally, nonviral gene delivery results in transient gene expression (TGE) of the antigen of interest. DNA vaccines were introduced in the late 90s, when Wolff, et al.[12] intramuscularly injected plasmid DNA (pDNA) in mice. Subsequently, Jiao, et al.[13] proposed the delivery of DNA plasmid to nonhuman primates, and Ulmer, et al.[14] described a vaccine against influenza using pDNA in mice. The following sections provide in-depth information about DNA vaccines: manufacturing and engineering DNA vaccines; safety and stability of DNA vaccines; kinetic control for DNA vaccine release; barriers for the delivery of pDNA vaccines; active nuclear transport for the nuclear uptake of DNA; controlling gene expression through plasmid engineering and gene circuits; techniques to overcome immunogenic issues of DNA vaccines; and the physical methods for DNA vaccine delivery in preclinical and clinical trials.

Pros: DNA vaccines have low production cost when compared to protein vaccines and enhanced stability for transportation and storage and can be administered to immunocompromised patients. Cons: low immunogenicity and may require multiple booster doses.

3. Mechanisms of internalization and processing

Figs. 2 and 3 delineate how the plasmid and the amino acid–based vaccine mechanisms of internalization and processing vary, in addition to the antigen presentation, respectively. Please note that in Fig. 2, certain cellular processes shown are generally for somatic cells (i.e., plasmid delivery), while other processes are for antigen presenting cells (APCs) (i.e., MHC I/II–peptide display). For example, the translated product within a somatic cell from a plasmid could transport extracellularly and then be uptaken by an APC.

A vaccine is processed by three main pathways: direct somatic cell engulfment/APC display (Fig. 2(1, 5, 3), thus leading to MHC II–peptide display); phagocytosis of a transfected (nonviral) or transformed (viral) cell/cross-priming (Fig. 2(1, 4, 6), thus leading to MHC I–peptide display); and Toll-like receptor (TLR) activation (Fig. 2(2, 7)). A vaccine may be taken up intracellularly by endocytosis within APCs (Fig. 2(1)) [15] or interact extracellularly by the TLR2/4 pathway, thereby resulting in the expression of proinflammatory cytokines and chemokines (interleukin (IL)-8/10, TNFα) (Fig. 2(2)). When nonviral gene delivery systems are used to deliver DNA vaccines, the proton sponge effect plays an important role for the pDNA to escape the endolysosomal degradation pathway (Fig. 2(3)). pDNA can be either randomly encapsulated by the nuclear envelope reforming postmitosis or actively transported to the nucleus through nuclear localization signals (i.e., DNA-targeted sequences – SV40 [16]). DNA vaccines may contain unmethylated CpG sequences that function as a pathogen–associated molecular pattern (PAMP) and can activate TLR9 in the endosome, eventually releasing IL-4 and interferon (IFN)α (Fig. 2(4)).
4. Enhancing the duration of immune protection using adjuvants

Enhancing the duration of immune protection by nonkinetic approaches can be achieved by (1) molecular immunostimulants (e.g., nucleic acids, polysaccharides, proteins, and polymers) and (2) advanced vaccine particles (e.g., nanoparticles, microparticles, and virus-like particles) (Table 2) [17,18].

4.1. Biopolymers

Biopolymers (i.e., polysaccharides and chitosan) are widely used for medical applications and have been reported to have adjuvant action in specific applications. For example, polysaccharide-based adjuvants can also improve the immunogenicity of vaccines. Chitosan is a known mucoadhesive and may exhibit important roles in mucosal immunization [82]. Sawaensak, et al. [19]
### Table 2
Examples of adjuvants [19–22,144–146,162–196].

| Adjuvant                  | Composition                                                                 | Disease          | Vaccine Type (commercial name)                                                                 | Immune response                                      | Research stage                                      | Year  |
|---------------------------|-----------------------------------------------------------------------------|------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------|-------|
| Alum                      | Alum, 3-O-desacyl-4′-monophosphoryl lipid A (AS04®) (GSK MPL®)               | Influenza A      | Virus-like particle (M2eVLP)                                                                   | Improved cross-protection                             | Murine                                             | 2014  |
|                           | Human Papillomavirus                                                         |                  | Protein vaccine (HPV-16 L1/HPV-18 L1) [GSK Cervarix®]                                        | Enhanced antibody response                            | Clinical study                                      | 2015  |
|                           | Toxoplasmosis                                                               |                  | DNA vaccine (toxofilin gene)                                                                  | Enhanced humoral response and switched from Th2 to Th1 | Murine                                             | 2016  |
|                           | Hepatitis B                                                                 |                  | Protein vaccine (HBsAg) [GSK FENDrix®]                                                        | Enhanced humoral and cell-mediated immune responses   | Clinical study                                      | 2017  |
|                           |                                                                            |                  |                                                                                               |                                                      |                                                     |       |
| Squalene oil-in-water     | Squalene, MONTANE 80, Eumulgin B1 PH (AF03®)                                 | Pneumonia        | Protein vaccine (PhlD)                                                                        | Increased frequency of CD4+ T cells and memory B cells | Phase I                                            | 2015  |
|                           | Squalene, MPL®, Saponin (QS21®)                                             | HIV-1C           | Protein vaccine (gp140)                                                                        | Enhanced humoral and cell-mediated immune responses   | Phase I                                            | 2016  |
|                           | Squalene, Tween 80, sorbitan triolate (MF59®)                                | Influenza A/HSN1 | Inactivated virus vaccine (SV)                                                                 | Increased levels of IL-6 and IL-10 within 24 h after vaccination | Phase I                                            | 2017  |
| Liposomes                 | MPL®, saponin (QS21®) (AS01®)                                               | Malaria          | Protein vaccine (RTS,S) [Mosquirix®]                                                           | Immunoprotection for 3–4 year infants, enhanced efficiency with booster | Phase III                                           | 2015  |
|                           | Squalene, glycerol, egg phosphatidylcholine, poloxamer, ammonium phosphate buffer (Stable Emulsion, SE) | Varicella zoster virus | Subunit vaccine (HZ/lsu) [GSK Shingrix®]                                                       | Significant immune protection in adults ≥50 years      | Phase III                                           | 2016  |
|                           | Squalene, Tween 80, α-tocopherol (AS03®)                                    | Tuberculosis     | Subunit vaccine (HS6/CAF01®)                                                                   | Longlasting immunoprotection and enhanced CD4+ T cell response | Phase I                                            | 2016  |
| TLR ligand                | GLA-AF (TRL4 ligand)                                                        | HIV clade C      | DNA vaccine/Attenuated vaccine/Protein vaccine (HIV env/gag-pol- nef, MVA-C, HIV CN54dp140)      | Enhanced T and B cell immune responses                | Murine                                             | 2014  |
|                           | dsRNA analog Poly(I:C) (TRL3 ligand)                                        | Seasonal influenza | Inactivated vaccine (TV)                                                                      | Enhanced humoral response                             | Murine                                             | 2014  |
|                           | Cpg 1018 (TRL9 ligand) (Dynavax HEPLISAV-B®)                                | Human Papillomavirus | Subunit vaccine (HIV-1 gp140)                                                                 | Longlasting IgG/IgA response                         | Murine                                             | 2016  |
|                           | Cpg 7909 (TRL9 ligand)                                                      | Hepatitis B      | Protein vaccine (HBsAg) [Dynavax HEPLISAV-B®]                                                 | Enhanced superior seroprotection                     | Phase III                                           | 2015  |
|                           | Cationic antimicrobial polypeptide/IC31® (TRL9 ligand)                      | Meningococcal infection | Subunit vaccine (dLPS/OMP)                                                                   | Early and increased IgG/IgM response                  | Phase I                                            | 2015  |
|                           |                                                                             | Tuberculosis     | Protein vaccine (H4:IC31®)                                                                    | High frequency CD4+ T cells and longlasting memory response | Phase I                                            | 2015  |
|                           |                                                                             |                  |                                                                                               |                                                      |                                                     |       |
|                           | Alum-absorbed GLA/SLA (TRL4 ligand)                                         | Malaria          | Protein vaccine (GMZ2.6C)                                                                     | Enhanced parasite-specific antibody and induced Th1 response | Murine                                             | 2016  |
|                           | Lipopolysaccharide Pam2/Pam3 (TRL2/6, TLR2/1 ligand)                        | Parasitic helminths Cancer | Autoclaved vaccine (ALM + Pam2/Pam3)                                                         | Th2 polarization                                      | Murine, parasite                                     | 2016  |
|                           |                                                                             |                  | Protein vaccine (DB125 WT-1)                                                                  | Infiltration of CD8+ T cells in tumor                 | Murine                                             | 2016  |
|                           |                                                                             |                  |                                                                                               |                                                      |                                                     |       |
|                           | Alum-absorbed GLA/SLA (TRL4 ligand)                                         | Human Papillomavirus | Subunit vaccine (HIV-1 gp140/HSV-2 gD)                                                          | Enhanced parasite-specific antibody and induced Th1 response | Murine                                             | 2016  |
|                           |                                                                             | Malaria          | Protein vaccine (GMZ2.6C)                                                                     | Th1 polarization                                      | Murine                                             | 2016  |
|                           |                                                                             |                  |                                                                                               |                                                      |                                                     |       |
|                           | Alum-absorbed SMIP7.10 (TRL7 ligand)                                        | Meningococcal infection | Conjugated polysaccharide vaccine (MenC-CRM197)                                             | Th1 polarization                                      | Clinical study (newborn)                            | 2016  |
|                           |                                                                             | Various          | Various                                                                                       |                                                      |                                                     |       |
| Poly saccharides          | Inulin (Advax®)                                                             | Hepatitis B      | Protein vaccine (HBsAg)                                                                       | Enhanced humoral and cell-mediated immune responses   | Clinical study                                      | 2014  |
|                           |                                                                             |                  | Seasonal influenza                                                                            | Low-dose TV/Advax® induced efficient immune response  |                                                      | 2016  |
reported nanoparticles of chitosan combined with tripolyphosphate and hemagglutinin (HA) induced a two-fold increase in the number of splenocytes that secrete IFNγ in mice infected with the influenza virus when compared with a nonadjuvanted HA vaccine [20]. Gordon, et al. [21,22] reported that inulin-based adjuvants (Advax®) elicit efficient immune responses against hepatitis B (Phase I). At least a fourfold increase in seroprotection was observed for subjects immunized with Advax® when compared to HBsAg alone. However, biopolymers have difficulties to control drug release owing to their solubility in water. For example, a report comparing pectin content demonstrated that higher pectin content resulted in increased erosion, thus leading to faster drug release; on the basis of the type of application, this concept can be an advantage or disadvantage depending on the length scale of drug release desired [23]. The reported pectin/amylase formulations released ~50%–100% of the drug within a 4 h timeframe in a gastrointestinal context.

4.2. Polymers

Relatively nontoxic and degradable (i.e., through hydrolysis of esters or amidolysis of amides) polymers such as poly(anhydride) (PA), poly-N-isopropyl acrylamide (PNIPAAm), and PLGA have found applications in vaccines. Tamayo, et al. [24] reported the recognition of PA nanoparticles by TLR2/4/5, thereby eliciting CD8+ T cell responses and Th1 polarization (for further information regarding Th1 polarization, refer to Fig. 3) in mice. Wafa, et al. [25] showed that the polymeric structure affects the intensity of the CD8+ T cell response and increased the protective duration. PA nanoparticles-based vaccines were recently employed for immunizing against swine influenza within pigs [26] and against H5N1 influenza [27]. Shakya, et al. [28] discussed the use of PNIPAAm combined with collagen type II as a polymeric adjuvant to reduce the risk of triggering autoimmune responses.

Several studies describe the enhanced immunogenicity due to the adjuvant properties of PLGA in comparison to nonadjuvanted antigen priming for subunit vaccines (recommended review article [29]). The size of PLGA particles (i.e., nano- or microparticle), as well as the monomeric L:G ratio played a crucial role in modulating immunogenicity [30]. Li, et al. [31] described an increase in Th1 cytokine expression (IFNγ and IL-17) to their pertussis toxoid vaccine by employing dual-range-sized particles ranging from 200 to 300 nm and 5 μm with a monomeric ratio of 50:50. Another example is that of Cruz, et al. [32], who reported an increased T-cell response by employing PLGA nanoparticles (50:50 L:G) for encapsulating and delivering a protein vaccine.

4.3. Molecular adjuvants for DNA vaccines

Ligands against TLRs, namely, TLR-3 and TLR-9, have been shown to improve immune response [33]. Cytokines such as interleukin (IL)-2, IL-12, and IL-15 encoded in plasmids have also shown to enhance immunogenicity [34,35]. Immune signaling molecules like TRIF and HMGB1 can also be encoded by the plasmid and have been successfully used as adjuvants along with DNA vaccines [36]. Genetic knockdown of genes, like PD-ligand 1 known to counteract DNA vaccines, using shRNA or siRNA has also shown to be effective adjuvants for DNA vaccines [37]. For further information with regard to adjuvants that are specifically used along with DNA vaccines, please refer to the following extensive review articles by Li et al: [38] and by Saade F. and Petrovsky N. [36].

(For sections 4.1–4.3) Pros: Similar to kinetic approaches, nonkinetic methods can also be used to achieve long-term and enhanced immune responses. Cons: adjuvants that are commonly used including alum and calcium salts can cause severe inflammation and are not compatible with, or advantageous for, certain antigens [39].

5. Manufacturing and engineering DNA vaccines

With continual improvements in DNA sequencing technology, we can better understand key conserved sequences that can be transcribed and translated into antigens and discover or engineer sequences that may be used for protection (i.e., TSO118 [40–42]). Nucleic acid code can be mass produced by DNA recombinant technology, and these codes can be directly delivered and subsequently processed and displayed by APCs for eventual seroconversion by the patient’s own transcription and translation machinery. Furthermore, peptides or proteins or subunits thereof can be mass produced in cells (i.e., E. coli and yeast) by DNA recombinant technology for manufacturing DNA vaccine.

Engineering and manufacturing DNA vaccines involve multidisciplinary fields such as molecular biology/biochemistry, separation techniques, and material science. A GOI can be inserted into a self-replicating organism (bacteria or yeast). A circular pDNA is usually...
used as the DNA cloning vector, which can then be extracted from the replicating organism and chemically purified [43]. The pDNA can be engineered to be expressed in bacteria (i.e., Escherichia coli (E. coli)) [44] or yeast (i.e., Pichia pastoris) [45,46] for amplification purposes in bioreactors and can also be expressed in mammalian cells for a therapeutic purpose. The major components involved within an engineered DNA plasmid are the origin of replication, promoter, GOI, and commonly an antibiotic resistance gene for selection [47]. As for E. coli-based plasmid production, the composition of the culture media can vary from mineral-containing media to complex mixtures supplemented with yeast extracts. After replication in the bioreactor, bacteria can undergo a lysing process through alkaline or thermal treatments, followed by plasmid purification through precipitation/centrifugation [48,49]. This large-scale pDNA production is cost-effective in comparison to LAV and IV manufacturing processes, possibly making the technology cheaper in the long run for consumers. The relatively recent development of minicircles (episomal DNA)/miniplasmids (i.e., P1, P7, and F)/ministrings [50–55] can potentially be transported more easily through cellular barriers to improve bioavailability [51].

For the sake of brevity, a discussion of downstream processing was omitted. Please refer to the following articles for further downstream processing information: [56–58].

6. Safety and stability of DNA vaccines

To date, there is no licensed DNA vaccine for use in humans [59,60]. The scientific community has high expectations for DNA vaccine use because of the following reasons: (1) the ability to control the transcribed and translated product, thereby controlling the ability of the antigen to not revert to a virulent pathogenic form; (2) the relatively low production cost of DNA vaccines; and (3) the innate stability of DNA vaccines for storage and transportation [61,62] purposes.

6.1. Auto-immunity

A potential disadvantage of DNA vaccines is that they could potentially trigger autoimmune diseases by eliciting anti-DNA antibody production, owing to the use of prokaryotic DNA vectors. Such vectors may contain unmethylated CpG sequences and may be recognized as a PAMP by the immune system (i.e., TLR9) leading to antibody production, owing to the use of prokaryotic DNA vectors. The scientific community has high expectations for DNA vaccines for storage and transportation [61,62] purposes in bioreactors and can also be expressed in mammalian cells for a therapeutic purpose. The major components involved within an engineered DNA plasmid are the origin of replication, promoter, GOI, and commonly an antibiotic resistance gene for selection [47]. As for E. coli-based plasmid production, the composition of the culture media can vary from mineral-containing media to complex mixtures supplemented with yeast extracts. After replication in the bioreactor, bacteria can undergo a lysing process through alkaline or thermal treatments, followed by plasmid purification through precipitation/centrifugation [48,49]. This large-scale pDNA production is cost-effective in comparison to LAV and IV manufacturing processes, possibly making the technology cheaper in the long run for consumers. The relatively recent development of minicircles (episomal DNA)/miniplasmids (i.e., P1, P7, and F)/ministrings [50–55] can potentially be transported more easily through cellular barriers to improve bioavailability [51].

For the sake of brevity, a discussion of downstream processing was omitted. Please refer to the following articles for further downstream processing information: [56–58].

6.2. Insertional mutagenesis of viral and nonviral delivery methods

DNA vaccines may cause indel mutations, the risks of which depend on the mechanism of delivery. Despite nonviral gene delivery systems being safer than viral vectors, risks of insertional mutagenesis are not zero, although the risks are believed to be lower than those of everyday random mutations. Unfortunately, often such nonviral risks are based on the insertion of a functional fluorescence-based marker where the entire functional sequence must be inserted not only within the genome but also into a region that is expressed. Nonviral risks of insertional mutagenesis may be higher than that currently believed. Such risks are also a function of the sequence and whether the DNA is supercoiled.

The administration of a DNA vaccine exposes the patient to foreign DNA or its fragments that could be inserted into the host's chromosomal DNA [70]. In the case of incorporation into an exon, an insertional mutation or a frameshift mutation occurs. Such mutations can cause a gene to malfunction or inactivate (i.e., a tumor suppressor gene). The insertion of foreign genes into the host genome could also lead to constituent expression of previously silent bacterial/parasite genes that have been inserted. The insertion may also increase the probability of rearrangements or breaking. The guidelines for industrial production of DNA vaccines published by the FDA recommend that the pDNA is supercoiled to more than 80% to help prevent insertional mutagenesis. It has been reported that the FDA recommends integration studies, regardless of the delivery method, if there are greater than 10,000 copies of foreign DNA per microgram of host DNA [71]. Interestingly, minicircle DNA [51,53,54,72,73] and ministring DNA [74,75] have been reported to have less risk of insertional mutagenesis because the major bacterial DNA (i.e., the unmethylated CpG repeats functioning as PAMPs) is removed.

6.3. Environmental stability (nonbiological)

DNA vaccines have an advantage of not requiring such rigorous temperature control as the protein-based vaccines require. However, the stability of nucleic acid–based vaccines under dry conditions (i.e., storage and transportation) or under aqueous conditions is highly dependent on stabilization techniques. Crine, et al. [76] reported the stability of purine sequence sites to remain undamaged for approximately 288–335 h at 37 °C, pH 7.21, and in a buffer solution that is similar to physiological media. Karni, et al. [77] investigated the thermal degradation rates of pDNA (0.75 μg of pUC19) and found that there was complete degradation after 9 min at 170 °C in an aqueous solution. When the pDNA was incubated at 200 °C under aqueous conditions, no intact pDNA could be found after 20 s. In the case of dried pDNA, the degradation temperature was reported to have a low threshold. They incubated pDNA and pUC19 at 10 °C increments for 5 min and found that pDNA started degrading at 130 °C and completely degraded at approximately 190 °C (in comparison to degradation at 95 °C). In addition, prokaryotic DNA was reported to be more thermally stable than eukaryotic DNA [78].

6.4. Biologically relevant stability

The stability of nucleic acids in the physiological environment depends on specific conditions at the intracellular, tissue, and systemic levels. In an in vivo environment, there is variation in pH (~5–7.45), exposure to various enzymes (i.e., nucleases) and reactive oxygen species, as well as the possibility of being epigenetically modified or modified by host DNA repair mechanisms [79].

The development of delivery systems for nucleic acids (e.g., polymeric and lipid vectors), which control the microenvironment of the nucleic acid, helps to maintain the molecular stability, as there is a decrease in the degradation rate when present in a complexed state (i.e., polyplex and lipoplex) versus a free state [80]. For example, the in vivo half-life for a nonionically complexed DNA is approximately 10 min in the extracellular environment, whereas the intracellular half-life is longer, close to 1–4 h. Despite the advantage in being in a complexed state in terms of its structural stability, if the DNA is excessively complexed, then successful transcription will not be as efficient, as the plasmid will not be accessible to the transcription machinery [81,82].

Evans, et al. [83] described the relevance of controlling the main mechanisms of DNA degradation (e.g., depurination/A-elimination
and free radical oxidation by employing chelators and hydroxyl radical scavengers). The use of ethanol and EDTA (ethylenediaminetetraacetic acid) or DTPA (diethylenetriaminepentaacetic acid) in DNA-based formulations is associated with enhancing the remaining DNA amount from approximately 30% to 70% after 1 month incubation at 50 °C.

Peptide nucleic acids (PNAs) are uncharged molecules that demonstrate increased resistance against nucleases and RNases in comparison to endogenous nucleic acid, which can have benefits for specific gene delivery and DNA vaccine applications. The conjugation of PNAs with cell-penetrating peptides (CPPs) can enhance the molecular stability and facilitate transfection [84]. In addition to being highly stable, CPP-conjugated PNAs have improved DNA sequence recognition and a higher affinity with lipid membranes because of the peptide backbone [85].

Epigenetic modifications affect the molecular stability and the genetic expression of DNA. Modifications such as DNA methylation are more likely to occur in CpG-rich regions [86], and the methylated regions may subsequently recruit DNA methylated-binding proteins and histone deacetylases (HDACs), which downregulate gene expression [87], as the transcriptional machinery cannot access the DNA.

7. Plasmid delivery

At a systemic level, eliciting specific antibody subtype responses depends on the contexts and routes of the delivery methods. For instance, a vaccine containing a Lactobacillus vector against the influenza A virus induces a higher survival rate in a murine model when administered through the intranasal route than through the oral route [88]. IgA titers were measured for the intranasal route in comparison to the intramuscular (IM) route after DNA vaccination [89]. Vaccines administered through the IM route can induce greater IgG2a titers, whereas a gene gun method can elicit a greater IgG1 antibody response [90].

At a cellular level, the transportation of highly charged macromolecules such as DNA across a negatively charged phospholipid bilayer membrane and subsequently through the highly restrictive nuclear envelope is challenging. More specifically, the main barriers for the delivery of pDNA vaccine are as follows: stability (described in the previous section), cellular uptake, endolysosomal escape, decomplexation from the carrier, and nuclear envelope translocation. The cellular uptake of nonviral gene delivery carriers can be uptaken through clathrin- or caveolae-mediated endocytosis, or macropinocytosis (endocytic pathways) [91,92]. Plasmids can be internalized within the nucleus through intranuclear injection, direct/indirect nuclear localization signals (i.e., DNA-targeted sequences), and encapsulation by the nuclear envelope upon reformation postmitosis [93].

7.1. Physical methods for DNA vaccine delivery

7.1.1. Electroporation

Electroporation (EP) causes transient pores in the plasma membrane of host cells to increase the uptake kinetics of pDNA under an electrical field. In a recent clinical trial, a DNA vaccine was delivered by IM-EP using Ichor Medical Systems TriGrid™ Delivery system (TDS-IM) [94]. The results demonstrated that the DNA vaccines delivered by EP are safe and effective for eliciting strong immune responses.

7.1.2. Gene gun

Another physical method developed to deliver plasmids epidermally is the gene gun [95]. A particle-mediated epidermal delivery (PMED) gene gun was used in preclinical trials to deliver a DNA vaccine against the dengue virus in nonhuman primates. Plasmids, including the oligonucleotide sequence of the vaccine antigen, were precipitated onto 1 μm-diameter gold beads. The DNA-adsorbed gold beads were then delivered using a gas-pressurized gene gun, which is a needle-free device [96]. The difference in PMED in terms of IM and intradermal injections using a needle and syringe is that PMED enables direct delivery of the vaccine into the intracellular environment more efficiently, thereby improving the cellular uptake and resulting in higher immune responses with substantially lower doses (100- to 1000-fold) of DNA [97]. Choi, et al. [98] compared three different delivery methods (IM, intradermal, and epidermal inoculation) using plasmid-coated gold beads through particle-pressurized bombardment (i.e., gene gun). The intradermal injection and gene gun resulted in specific IgG antibody responses but not IgA. Despite the induction of IgG responses, both the gene gun and intradermal administration methods failed to protect mice from a rotavirus infection in that particular study.

Other physical methods have included physically puncturing the cells by using microneedles (impalation) [99], hydrostatic pressure, squeezing cells in a microfluidic chamber (in addition to EP) [100], sonoporation [101], and intranasal delivery [38]. For interested readers regarding physical methods for intracellular delivery, we would recommend the publications from Meacham, et al [102,103].

(For sub-sections 7.1.1–7.1.2) Pros: EP and gene gun are safe to use for delivering DNA and have shown immune responses in specific applications. EP requires less DNA without compromising efficacy. Cons: EP is often invasive and limited for in vivo applications and may lead to cell death. The gene gun method has limited or no control over the insertion sites of the DNA and is relatively expensive [104].

7.2. Nonviral methods (lipid- and polymer-based)

Lipids or cationic, amine-containing polymers are often complexed with anionic plasmid macromolecules into nanosized particles, and this facilitates cellular uptake and inhibits the degradation of the plasmid during trafficking both extracellularly and intracellularly. In an uncomplexed state, half-lives of plasmids extracellularly in serum and intracellularly is in the order of a few minutes and hours, respectively. The mass of free polymer carrier in the solution is critical for the delivery efficiency and is typically administered in manyfold excess for transfection to occur. Owing to the need for free polymer to be in excess, despite taking advantage of the enhanced permeability and retention effect for the larger polyplexes, the free polymer is not able to sufficiently transport to the site of interest [105]. For this reason, nonviral gene delivery systems are often injected locally. Furthermore, many researchers have endeavored to improve the buffering capacity, but generally, the carriers are excessively toxic by doing so. Interested readers may refer to the following review for further information with regard to nonviral gene delivery barriers [82,106,107]. The following paragraphs discuss cell specificity, hydrophobicity, the proton sponge effect, and nuclear uptake for the readers’ convenience.

7.2.1. Cell specificity of nonviral gene delivery systems

With regard to cell specificity, surface modifications can be employed for enhancement of uptake and structures of the carriers can be screened by using high-throughput methods to discover cell specificity [108]. Guerrero-Cázares, et al. [109] demonstrated that biodegradable poly(beta-amino ester) nanoparticles present specific transfection efficacy to human brain tumor-initiating cells compared to noncancerous cells. Similar results were also reported in a previous work on hepatoma cells [110] and glioblastoma cells [111]. The exact mechanisms of chemical structure-related cell specificity remain unknown. However, it is important to note that
the cell specificity of the nonviral gene delivery system was not due to factors such as cellular division rate, cellular uptake amounts of nanoparticles, or media composition. Although the exact mechanism remains elusive, it is hypothesized that different pathways of endocytosis, tuned by different polymer structures, may be the answer to the cell specificity differences. Understanding the Structure Activity Relationships (SARs) is an ongoing endeavor within the field. Enabling the ability to engineer optimized delivery systems is the objective in elucidating such SARs.

7.2.2. Hydrophobicity of nonviral gene delivery systems

An analysis of the interaction of the cell membrane with amphiphilic materials has demonstrated that adsorption of hydrophobic moieties (i.e., Lipofectamine2000®/3000®, lipid-based systems, or a greater number of carbons in the polymer backbone or side chain) can cause disruption or destabilization of the cell membrane, thereby facilitating endosomal uptake [81,112,113]. Therefore, promoting cellular uptake is often accomplished by using polymers or lipids designed to increase the interaction between nanoparticles and the cell membrane [82]. Hydrophobicity is one of the main variables that is varied to optimize a nonviral gene delivery system.

7.2.3. Proton sponge effect for nonviral gene delivery systems

After internalization through an endocytic pathway, the pDNA needs to efficiently escape from the endolysosomal degradation pathway into the cytoplasm to avoid degradation. Several authors have observed enhanced endosomal escape using polyethyleneimine (PEI) conjugated to the pDNA to further enhance the “proton sponge effect,” which promotes endosomal swelling and rupture [114]. This effect occurs because of the buffering capacity of the unprotonated amine groups on PEI. The PEI becomes increasingly protonated during the acidification process of the endosomes and thus imbalanced osmotic pressure differences form across the membrane. This is due to influx of Cl\(^-\) ions and water molecules into the endosome [115]. Other escape mechanisms have involved fusogenic peptides. For example, Nakase, et al. suggested the association between PEI and the fusogenic peptide GALA on the cationic lipid-coated exosomes, which increased endosomal escape of exosomes that are useful for nucleic acid delivery [116], Hu, et al. [117] developed a DNA vaccine against malignant melanomas employing TAT-based fusogenic peptides with PEI-mannose nanoparticles adsorbed onto microneedles [118]. The use of the TAT-based fusogenic peptide resulted in T-cell activation and enhanced expression of IFN\(\gamma\) IL-12 [119].

7.2.4. Nuclear uptake

A nuclear localization sequence can also be indirectly incorporated into the pDNA by using DNA targeting sequences (DTSS) [120]. A DTS is a DNA subsequence that can be incorporated into the pDNA and is a binding site for NLS-containing protein. Presumably, after the DNA is separated from the complex, karyopherins are able to help facilitate the nuclear uptake of the plasmid. This technology was derived from viruses, for example, the simian virus 40 (SV40), which has a DTS within its genome [80,121], uses this mechanism to improve its ability to replicate. Thus, when the SV40 DTS sequence (5′-AACGACCTGAAATGTGTCATGGGTTGATGAAAGTCCCGAGCTCCTCCCACAGCGAAGAATGTGCAAAAGCT-3′) is incorporated into the pDNA of interest, improved gene transfection can similarly be observed (in some cell types) [122].

(For sub-sections 7.2.1–7.2.4)

Pros: Nonviral delivery systems are relatively safer to use than their viral counterparts and benefit from being more cost-effective and easier to chemically modify and optimize. Cons: Nonviral systems generally result in temporary expression and also relatively lower expression during the period of expression [123].

8. Controlling gene expression through plasmid engineering and gene circuits

Designing a plasmid entails the selection of the DNA insert or the GOI, the DNA vector or backbone of the plasmid, the transformation protocol (which depends on the species of the host organism (i.e., competent cells are often used for transformation in \(E.\) coli)), and the host organism (i.e., bacteria (\(E.\) coli) or yeast (\(P.\) pastoris)).

8.1. Minicircle DNA and CpG repeats

Relatively recent technologies suggest that the use of minicircle DNA increases therapy biosafety because bacterial DNA is removed from the parental plasmid such that only the GOI and promoter/terminator sequences essentially remain [124]. Because parental bacteria sequences are absent to a greater extent, the lack of CpG sequences has resulted in longer half-lives of the plasmid. However, for specific applications, encoding CpG is desirable for enhancing the immunogenic response. Moreover, studies have demonstrated that gene transfer using minicircles induces a 10- to 1000-fold increase in the long-term transgene expression in vivo and in vitro when compared to pDNA for specific applications, which can potentially improve the immunogenicity of DNA vaccines [125].

To improve pDNA TGE efficiency, early studies investigated various combinations of promoters/enhancers to control gene expression, as well as the TGE efficiency for HIV-1 vaccination [126,127]. Sun, et al. [128] and Li, et al. [129] reported the use of post-translational regulatory elements to improve the efficiency of DNA vaccines. Such approaches will likely benefit the field.

8.2. Codon optimization

Codon optimization adapts DNA sequences between species to augment expression. Amino acids are coded by synonymous genetic codons, and the frequency of the synonymous codon being used depends on the species. Gene expression can be optimized by utilizing the advantage of information of codon usage in specific organisms. During the plasmid design, low-frequency eukaryotic codons in the foreign DNA backbone are identified and replaced for high-frequency codons, while still maintaining their respective amino acids [130–132]. There has been recent progress in terms of enhancing the immunogenicity in mice and chicken primed with such codon-optimized DNA vaccines [133–135].

8.3. Synthetic biology

Synthetic gene circuits provide tools for accurately controlling gene expression [136]. The plasmid sequence itself can be engineered to control the expression (i.e., CRISPR/Cas9 technology) [137–139]. For example, Brophy and Voigt [140] constructed a gene circuit in \(E.\) coli with an antisense promoter placed next to the terminator to study the function of antisense promoters as regulators. The same group has also worked on designing computational tools such as the python language-based “DNAplotlib” library to visualize the gene circuit outline [141]. Another application using gene circuits and synthetic biology is the orthogonal polymerases, which independently control multiple pathways in the same cell [142]. Using multiple activator-chaperone pairs has also been observed to improve the orthogonality in gene circuits [143]. Moon, et al. [144] used a four-input AND gate that controlled the orthogonal gene expression of multiple pathways at the same time, independent of one another, employing \(E.\) coli.
Deans, et al. investigated a mechanism that enables control over the gene expression profile through engineered inducers within genetic circuits [136], thus demonstrating the potential to switch a GOI on/off through molecular controllers. Such applications could potentially enable the regulation of the immune response in terms of intensity and type (cell mediated/humoral) in the future for vaccine applications. Recently, synthetic biology has been widely used for genetic engineering applications to conduct developmental and functional studies. (For sub-sections 8.1–8.3) Pros: Plasmid engineering is a potential method to control gene expression, but currently, technology is generally limited to nontherapeutic genes. As this nascent field continues to grow, there will likely be great improvement in terms of controlling expression as a function of the presence or absence of key entities. Synthetic biology provides a number of tools, such as CRISPR, to efficiently add or delete the GOI. Cons: Extraneous mutations (i.e., indels) can often occur in technologies, such as CRISPR, thereby leading to severe side effects. The complexity of certain gene circuits can lead to unreliable gene expression and safety concerns regarding specificity and off-target effects which will need to be thoroughly investigated.

9. Techniques to overcome immunogenic issues of DNA vaccines

Despite the positive outlook, DNA vaccines have low immunogenicity and hence require immunostimulant adjuvants and/or additional priming or boosters. The immunostimulants and adjuvants, depending on the type, may require more complex storage and transportation conditions. Methods involving the use of cytokines (i.e., IL-4) or the granulocyte-macrophage colony-stimulating factor (GM-CSF) have proven useful in enhancing the immune response. For example, Kalams, et al. [144] reported that IL-12 and/or IL-15 produced a safe and immunogenic response for their HIV-1 Gag DNA vaccine. Kalams, et al. also evaluated the positive impact of EP delivery methods for the HIV-1 Gag antigen/IL-12 adjuvant plasmid vector in a phase I clinical trial. Other studies have also assessed the immunogenicity of DNA vaccines containing chemokine-expressing sequences for HIV-1 immunization [144–146]. The CpG oligodeoxynucleotide (ODN) is another common genetic adjuvant used for DNA vaccines [9,147,148]. Preclinical studies have demonstrated that CpG ODN activates TLR9-bearing B cells and plasmacytoid dendritic cells and further support the induction of strong Th1-type responses [149]. In addition to engineering the ratio of CpG motifs in DNA vaccines to improve immunogenicity, administering additional synthetic CpG ODNs or co-administering a second plasmid cloned with CpG motifs has been investigated. Kojima, et al. delivered a CpG-encoding plasmid 2 days and 4 days both before and after an HIV DNA vaccine was delivered (as well as at the same time). Results showed that a significant boost of HIV-specific IgG and cytotoxic T lymphocyte activity can be obtained when the CpG plasmid was administered either 2 or 4 days after HIV DNA vaccination [150].

Consecutive immunization by using a prime/boost strategy is also applied in many clinical trials to overcome poor immunogenicity of DNA vaccines. The immunization involves priming by a DNA vaccine followed by boosting with (recombinant) antigenic protein [151]. For example, Dale, et al. investigated the use of pDNA and recombinant fowlpox virus (rFPV) vaccines as potential HIV-1 vaccine candidates; their group demonstrated this prime-boost vaccine system can induce stronger antigen-specific T-cell responses [152]. A large and immediate T-cell immune response was observed after administering the rFPV boost in macaques 12 days after priming with DNA vaccines. However, a similar boost in immunity may not be obtained while reboosting with a second dose of the same recombinant protein vaccine. This suggests that the doses and the intervals between doses for multiple boosting vaccinations need to be further evaluated.

10. Examples of DNA vaccine commercial successes

According to the DNA vaccine database, DNAVaxDB [153], there have been more than 20,000 articles related to DNA vaccine, up to and including the year 2017, indexed in PubMed and Google Scholar. However, to the extent of our knowledge, there has not yet been a licensed DNA vaccine for use in humans in the U.S., Europe, or Japan. Because the gene-based formulations require greater safety evaluation than conventional vaccines (e.g., nucleic acid integration into the host’s chromosomal genome), the timeline for approving DNA vaccines for humans is relatively lengthy. While

| Vaccine Type | Vaccine Target | Product Name | Administration | Date of Approval | Company involved |
|--------------|----------------|--------------|----------------|------------------|-----------------|
| Human        |                |              |                |                  |                 |
| Live attenuated vaccine | Cholera | Vaxchora® | Oral | 2016 | PaxVax |
| Inactivated vaccine | Influenza | FluMist® | Intranasal | 2003 | MedImmune |
| Inactivated hepatitis A and recombinant protein | Hepatitis A and B | Flucelvax® | Intramuscular | 2012 | Novartis |
| Toxoid conjugated vaccine | Invasive meningococcal disease | Fluzone® | Intradermal | 2002 | Sanofi Pasteur |
| Polysaccharide vaccine | Meningococcal Group B | Twinrix® | Intramuscular | 2001 | GlaxoSmithKline |
| Recombinant proteins | Streptococcus pneumoniae | Menveo® | Intramuscular | 2010 | Novartis |
| DNA vaccine | West Nile virus | Bexsero® | Intramuscular | 2015 | Novartis |
| Animal       |                |              |                |                  |                 |
| DNA vaccine | Infectious haematopoietic necrosis virus (IHNV) | Oncept® | Dogs | 2010 | Merial |
| DNA vaccine | Growth hormone releasing hormone (GHRH) | LifeTide® | Salmon | 2005 | Novartis |

Table 3

Recent licensed protein and DNA vaccine therapies (data extracted from 2001 to 2017; some of which are not related to infectious diseases).
Table 4
Selected current DNA vaccines progressing through Phase I to III clinical trials.

| Human | Product name | Vector name | Vaccine formulation | Delivery method | Clinical status | Trial number | Sponsor |
|-------|--------------|-------------|---------------------|-----------------|-----------------|--------------|---------|
| HIV infection (Prophylactic vaccine) | PENNVAX®-B | – | DNA vaccine | CELLECTRA® intramuscular electroporation device | Phase I | NCT01082692 | Inovio Pharmaceuticals |
| | PENNVAX®-GP | – | DNA vaccine + plasmid cytokine adjuvant (IL-12) | CELLECTRA® intramuscular electroporation device | Phase I | NCT02431767 | Inovio Pharmaceuticals |
| Malaria (Prophylactic vaccine) | EP-1300 | – | DNA vaccine | Intramuscular injection with electroporation via TriGrid™ Delivery System (TDS) | Phase I | NCT01169077 | KAEL-GemVax |
| Hepatitis B (Therapeutic immunotherapy) | INO-1800® | – | DNA vaccine + plasmid cytokine adjuvant (IL-12) DNA vaccine only | CELLECTRA® intramuscular electroporation device | Phase I | NCT02431312 | Inovio Pharmaceuticals |
| Zika virus infections (Prophylactic vaccine) | GLS-5700® | pGX7201 | DNA vaccine only | Intramuscular injection with electroporation | Phase I | NCT02809443, NCT02887482 | Inovio Pharmaceuticals GeneOne Life Science, Inovio Pharmaceuticals |
| Middle East respiratory syndrome coronavirus (MERS CoV) (Prophylactic vaccine) | GLS-5300® | – | DNA vaccine only | Intramuscular injection with electroporation | Phase I | NCT02670187 | Inovio Pharmaceuticals |
| Influenza A H5N1 and H1N1 subtypes (Prophylactic vaccine) | INO-3510® | – | DNA vaccine only | Intradermal injection with electroporation | Phase I | NCT01405885 | Inovio Pharmaceuticals |
| Viral hemorrhagic fever with renal syndrome (Prophylactic vaccine) | HTNV/PUUV DNA Vaccine pWRG/HTN-M (co)/pWRG/PUUV-M(s2) | DNA vaccine only | Intramuscular injection with electroporation via TriGrid™ Delivery System (TDS) | Phase II | NCT02116205 | Ichor Medical Systems US Army Medical Research and Materiel Command Astellas, Pharma Vical |
| Cytomegaloovirus infection in hematopoietic cell transplantation/solid organ (kidney) transplantation | ASP0113 | TransVax | DNA vaccine with poloxamer-based CRL11005 delivery system | Intramuscular injection | Phase III | NCT01877655, NCT01974206 | Inovio Pharmaceuticals |
| HSV-2 infection (Therapeutic vaccine) | herpes simplex bivalent DNA vaccine | VCL-HB01 | DNA vaccine only | Intramuscular injection | Phase II | NCT02837575 | Vical |
| DNA vaccine priming and other vaccine boosting | DNA vaccine prime + MVA vaccine boost | GOVX-B11 pGA2/JS7 | Intramuscular injection | Phase II | NCT00820846 | GeoVax |
| HIV infection (Prophylactic vaccine) | PENNVAX®-G | – | DNA vaccine prime + MVA-CMDR vaccine boost | Intramuscular delivery by Biojector 2000® needleless device/CELLECTRA® intramuscular electroporation device | Phase I | NCT01260727 | Inovio Pharmaceuticals |
| | – | – | DNA vaccine prime + adenovirus type 5 vaccine (Ad) boost | Intramuscular delivery by Biojector 2000® needleless device | Phase I/IIa | NCT00870987 | Vical, U.S. Army Medical Research and Materiel Command |

Table 3 to provide a wholistic picture of the current progress of DNA animal vaccines.

To date, there have been 462 clinical trials (early phase to phase IV; search term: “DNA vaccine”) according to ClinicalTrial.gov. The U.S. was responsible for 248 of these clinical trials. Studies which have been suspended, terminated, withdrawn, or have an unknown status are excluded from these numbers. Details on patented and/or sponsored DNA vaccine technologies are summarized in Table 4. The majority of these trials (13 of 18 selected trials) are investigating prophylactic vaccines for infectious diseases (i.e., HIV, influenza, and hepatitis B infections). A detailed analysis of clinical trials of gene-based prophylactic vaccines (including virus vaccines) was reported by Nakayama, et al. in 2015 [157].

To date, most clinical trials have demonstrated no significant evidence indicating DNA insertional mutagenesis into the chromosomes of hosts and immunologic tolerance in terms of developing anti-DNA antibodies. However, the transfection efficiency of DNA vaccines are still being evaluated in clinical trials, to the extent of our knowledge, there have been four DNA vaccines approved for veterinary applications. Overviews of DNA vaccines approved for animal models have been reported in several articles [154–156]. These approved DNA vaccines are for a number of species including equine, salmon, porcine, and canine. The earliest DNA vaccine approvals were obtained in 2005, namely, the West Nile–Innovator® (equine) and Apex-IHN® (salmon). These two vaccines are prophylactic vaccines for infectious diseases encoding subcomponents of the viral proteins for generating antibodies against the West Nile Virus and the infectious hematopoietic necrosis virus, respectively. In 2008, a single dose of vaccine expressing the growth hormone LifeTide® SW5 (i.e., porcine) was licensed for gene therapy. The latest approval was in 2010, namely, Onccept® (canine), which is used for cancer immunotherapy against oral melanoma (Table 3). Although the noninfectious vaccines are not the main focus of this review, the two vaccines are included in Table 3 to provide a wholistic picture of the current progress of DNA animal vaccines.
plasmids is generally poor resulting in an insufficient induction of an immune response, which is possibly one of the greatest challenges in current clinical trials. As a result, more trials have been utilizing hybridized formulations (i.e., CpG) and/or higher DNA doses for greater expression levels and immunogenicity [151]. A number of current clinical trials for HIV infections are an example of such endeavors. The GOVX-B11 vaccine, currently in phase II, constitutes two components: a DNA vaccine used to prime a person’s immune response and a recombinant MVA (modified vaccinia Ankara, attenuated vaccine) used to boost the primed response. Their studies were conducted in HIV-infected participants who were currently undergoing antiretroviral treatment. It has been demonstrated that GOVX-B11 is capable of eliciting antibodies and a T cell response against a heterologous challenge [158]. On the other hand, the PENNVAX DNA vaccines developed by Inovio Pharmaceuticals, currently in phase I, utilize the prime-boost strategy, similar to that of GOVX-B11, by combining a viral vector vaccine. Furthermore, Inovio demonstrated that the immune response can be enhanced when PENNVAX is delivered in vivo by intradermal EP compared to a syringe injection [52,159]. These results reveal that the modification of DNA vaccine formulations or combinatorial delivery approaches can improve the potency and efficacy of DNA vaccines in human clinical trials.

In summary, as of 2017, a large number of second-generation vaccines have been licensed and released on the market. Some of these DNA vaccines have also been approved for sale for animal health applications (summarized in Tables 2 and 3). These reports provide evidence for the potential and growth of a market for new vaccine technologies. Regarding the feasibility of current trials of DNA vaccines, further advancement of plasmid formulations and delivery approaches will be necessary for the DNA vaccine platform to be realized within humans.

11. Conclusion and future directions

The optimization of vaccine scheduling has been generally limited to investigations where time was varied by month [160]. Optimizing vaccine schedules with smaller steps in time will likely result in enhanced seroconversion and protection. In terms of engineering the kinetics for vaccines by auto-boosting technologies, the practicality of receiving doses on short time scales is increasingly more reasonable. New technologies such as SEAL [161] are seriously needed and are likely to be highly impactful. Potential complications such as the junction of the seal must be mitigated to the extent possible, however. Removal of the need to seal would be more reasonable. Direct injection systems and microfluidic-based technologies

Enhancing the ability to stabilize the cargo within is challenging. Having a depot environment that is optimized and catered to a given antigen is possible within a depot vaccine system in terms of excipients and cryoprotectant content, as well as ratios of excipients to antigen. However, if multiple antigen types are to be delivered from the vaccine depot, it is highly challenging to cater to multiple antigen types in the most optimal fashion within a single depot. Endeavors to deliver vaccine depots with environments that are most optimally catered to each specific antigen within a given injectable vaccine system would also be beneficial and challenging from an engineering standpoint.

To date, although clinical translation of gene-based systems has been limited, the U.S. has recently approved two gene therapies. As more gene-modulating technologies receive approval, obtaining 510(k) clearance will be increasingly common for this field. DNA vaccines, although promising, suffer limitations owing to their inability to be sufficiently immunogenic. Techniques to engineer DNA-based systems such as prime/booster methods, as well as the incorporation of adjuvants (transcribed/translated or codelivered), will continue to improve the immunogenicity for attaining protective seroconversion.

Currently, safety assessments for gene delivery systems undergoing approval processes are arduous to determine risks of insertional mutagenesis. Although gene sequencing is becoming increasingly cheaper over the years, conducting qRT-PCR or qPCR is time consuming and requires relatively more sophisticated instrumentation in comparison to fluorescence-based assays. Endeavoring to properly assess insertional mutagenesis risks for gene-modulating technologies would probably be highly useful if the assay is fluorescence-based and sufficiently reliable.

To further the development of vaccines with improved functionality, an interdisciplinary-focused research will be of great utility. In light of research discussed herein, the vaccine realm will be experiencing great improvements in the following areas in the coming years: further optimization of vaccine scheduling; duration of protection through nonkinetic approaches; enhancement of antigen stability; improved immunogenicity of DNA vaccines; manufacturing and engineering vaccines in general, and the ability to control gene circuits for gene-modulating technologies.

References

[1] Disease Burden and Mortality Estimates, http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html, 2016.
[2] 10 Facts on Polio Eradication, http://www.who.int/features/factfiles/polio/en/, 2017.
[3] The Vaccines, http://polioeradication.org/polio-today/polio-prevention/the-vaccines/opv/, 2016.
[4] P.D. Minor, Live attenuated vaccines: historical successes and current challenges, Virology 479–480 (2015) 379–392.
[5] L. Watson, B.J. Wilson, N. Waugh, Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults, Vaccine 20 (17–18) (2002) 2166–2173.
[6] C.C. Daniels, P.D. Rogers, C.M. Shelton, A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens, J. Pediatr. Pharmacol. Ther 21 (1) (2016) 27–35.
[7] H.W. Cho, C.R. Howard, H.W. Lee, Review of an inactivated vaccine against hantaviruses, Intervirology 45 (4–6) (2002) 328–333.
[8] M.A. Liu, DNA vaccines: a review, J. Intern. Med. 253 (4) (2003) 402–410.
[9] Y. Qiu, L. Guo, S. Zhang, B. Xu, Y. Gao, Y. Hu, J. Hou, B. Bai, H. Shen, P. Mao, DNA-based vaccination against hepatitis B virus using dissolving microneedle arrays adjuvanted by cationic liposomes and CpG ODN, Drug Deliv. 23 (7) (2016) 2391–2398.
[10] A. Endmann, K. Klander, K. Kapp, O. Riede, D. Oswald, E.G. Talman, M. Schroff, C. Kleuss, M.H. Ruters, C. Juhls, Cationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccine, PLoS One 9 (7) (2014) e101715.
[11] K. Khatri, A.K. Goyal, P.N. Gupta, N. Mishra, S.P. Vyas, Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B, Int. J. Pharm. 354 (1–2) (2008) 235–241.
[12] J.A. Wolf, R.W. Malone, P. Williams, W. Chong, G. Acsa, A. Jani, P.L. Felgner, Direct gene transfer into mouse muscle in vivo, Science 247 (4949 Pt 1) (1990) 1465–1468.
[13] S. Jiao, P. Williams, R.K. Berg, B.A. Hodgeman, L. Liu, G. Repetto, J.A. Wolf, Direct gene transfer into nonhuman primate myobiffers in vivo, Hum. Gene Ther. 3 (1) (1992) 21–33.
[14] J.B. Ullner, J.J. Donnelly, S.E. Parker, G.H. Rhodes, P.L. Felgner, V.J. Dwaraki, S.H. Gromkowski, R.R. Deck, C.M. DeWitt, A. Friedman, et al., Heterologous protection against influenza by injection of DNA encoding a viral protein, Science 259 (5102) (1993) 1745–1749.
[15] M.A. Dobrovolskaia, S.E. McNeil, Immunological properties of engineered nanomaterials, Nat. Nanotechnol. 2 (8) (2007) 469–478.
[16] Y. Xu, W. Liang, Y. Qiu, M. Cеспi, G.F. Palmieri, A.J. Mason, J.K. Lam, Quantification of pulmonary fibrosis in a bleomycin mouse model using automated histological image analysis, PLoS One 12 (1) (2017) e0170561.
[17] A. Gabattini, E. Pettini, F. Fiorino, G. Pastore, P. Andersen, G. Pozzi, D. Meda, llinia, Modulation of primary immune response by different vaccine adjuvants, Front. Immunol. 7 (2016) 427.
DNA vaccines in veterinary use, Exp. Rev. Vaccines 8 (2013) 120–127.

L. Morris, D.B. Weiner, DNA vaccines: ready for prime time?, Nat. Rev. Genet. 9 (10) (2008) 776–788.

Y. Nakayama, A. Aruga, Comparison of current status for regulatory use for gene-based vaccines in the US, Europe and Japan, Vaccines 3 (1) (2015) 186–202.

K. Li, L. Gao, H. Gao, J. Fu, Y. Hu, Y. Liu, Y. Shao, Posttranscriptional regulatory elements enhance antigen expression and DNA vaccine efficacy, DNA Cell Biol. 28 (5) (2009) 233–240.

K. Li, L. Gao, H. Gao, J. Yang, J. Liu, Y. Li, Y. Wang, X. Wang, Codon optimization and woodchuck hepatitis virus posttranscriptional regulatory element enhance the immune responses of DNA vaccines against infectious bronchitis virus in chickens, Vaccine 33 (39) (2015) 5234–5240.

R. Grantham, C. Gautier, M. Gouy, R. Mercier, A. Pave, Codon catalog usage and the genome hypothesis, Nucl. Acids Res. 8 (1) (1980) 1–62.

T. Nagata, M. Uchijima, A. Yoshida, M. Kawashima, Y. Koide, Codon optimization enhances the translation efficiency of DNA vaccine in mammalian cells: analysis of plasmid DNA encoding a CTL epitope derived from microorganisms, Biochem. Biophys. Res. Commun. 261 (2) (1999) 445–451.

T.M. Jacobs, H. Yumerfendi, B. Kuhlman, A. Leaver-Fay, Swiftfold: rapid degenerate-codon-library optimization through dynamic programming, Nucl. Acids Res. 43 (5) (2015) e34.

D. Hannaman, L.C. Dupuy, B. Ellefien, S.C. Schmaljohn, A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation, Vaccine 34 (31) (2016) 3607–3612.

D. Datta, G.P. Bansal, D.L. Gerloff, B. Ellefien, D. Hannaman, N. Kumar, Immunogenicity and malaria transmission reducing potency of Pfethyl/45 and PfM5 encoded by DNA vaccines administered by intradermal electroporation, Vaccine 35 (2) (2017) 264–272.

A. Stachyra, P. Redkiewicz, P. Kossos, A. Protasius, A. Gora-Sochacka, G. Karwowska, W. Sitko, CpG motif-induced antigen presentation in bone marrow-derived dendritic cells in mice: functional and immunogenic properties of mouse DNA vaccine against avian influenza virus H5N1 in mice and chickens, Virol. J. 13 (1) (2016) 143.

T.L. Deans, A. Singh, M. Gibbon, J.H. Elskieff, Regulating synthetic gene networks in 3D materials, Proc. Natl. Acad. Sci. U.S.A. 109 (38) (2012) 15217–15222.

T.L. Deans, C.R. Cantor, J.J. Collins, A tunable genetic switch based on RNA and repressor proteins for regulating gene expression in mammalian cells, Proc. Natl. Acad. Sci. U.S.A. 104 (2) (2007) 711–7121.

M.J. Smanski, S. Bhatia, D. Zhao, Y. Han, C. Nilsson, B. Hejdeman, K. Godoy-Ramirez, T. Tecleab, G. Scarlatti, A. Bråve, P. Racz, X. Li, M. Patel, Z. Xiang, Y. He, DNAVaxDB: the first web-based DNA vaccine database and the genome hypothesis, Nucl. Acids Res. 8 (1) (1980) r49–r62.

D. Verthelyi, Adjuvant Properties of CpG Oligonucleotides in Primates, DNA Vaccines, Springer, 2006, pp. 139–158.

D. Apter, C.M. Wheeler, J. Paavonen, X. Castellsague, S.M. Garland, S.R. Saikku, M. Elizaga, B. Metch, S. Edupuganti, J. Hural, S. De Paoli, J. Kukkonen, M.J. Smanski, S. Bhatia, D. Zhao, Y. Park, B.A. Woodruff L, G. Giannoukos, D. Kudla, A. Sirko, Codon optimization of antigen coding sequences improves the immune potential of DNA vaccines against avian influenza virus H5N1 in mice and chickens, J. Virol. 83 (10) (2009) 5108–5112.

Y. Kojima, K.-Q. Xin, T. Ooki, K. Hamajima, T. Oikawa, K. Shinoda, T. Ozaki, Y. Hoshino, N. Jounai, M. Nakazawa, Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine, Vaccine 20 (23–24) (2002) 2857–2865.

M.A. Liu, J.B. Ulmer, Human clinical trials of plasmid DNA vaccines, Adv. Genet. 55 (2005) 25–40.
